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A B S T R A C T
Background: Regulation of the hypothalamic-pituitary-adrenal (HPA) axis is implicated in the pathogenesis of
bipolar disorder (BD). However, the relationship between HPA-activity and disease severity is not fully eluci-
dated. In this pilot study we aimed to explore the temporal relationship between HPA-activity and the risk of a
manic episode in BD patients type I, by assessing long-term hair cortisol concentrations (HCC). Second, we
explored the relation between HCC and the number of previous episodes.
Methods: Hair samples were collected from 45 BD I patients in euthymic or manic state and compared to 17
controls. From each participant, two hair samples of 3 cm length were used to measure long-term cortisol,
reflecting retrospect time frames of 1–3 months and 4–6 months respectively prior to sampling.
Results: HCC in the BD group was slightly higher than in the control group in both hair segments (p = 0.049 and
0.03; after adjustment for age, sex, BMI and hair washing frequency p = 0.222 and 0.139). A significant peak in
hair cortisol was observed prior to a manic episode (p = 0.036). Furthermore, we found a positive correlation
between the number of mood episodes HCC (p = 0.03).
Conclusions: Our results indicate that long-term cortisol levels are slightly higher in BD, and in particular ele-
vated in the months prior to a manic relapse. In addition HCC are positively associated with the number of
previous mood episodes in the course of BD type I.
1. Introduction
Bipolar Disorder (BD) is a severe mental illness, characterized by a
chronic and unpredictable course. Understanding the pathophysiolo-
gical processes is crucial to identify new potential therapeutic targets.
Current pharmacological and psychotherapeutic treatment results in
long term stability in only one third of BD patients, leaving two thirds in
urgent need of novel treatment options (Renes et al., 2014).
Endocrine systems seem to play a role in the pathogenesis of BD.
The hypothalamus – pituitary – adrenal (HPA) axis, as one of the key
systems, shows an altered functioning, characterized by higher cortisol
levels (Belvederi Murri et al., 2016; Cervantes et al., 2001; Daban et al.,
2005; Deshauer et al., 2003; Jabben et al., 2011; Langan, McDonald
2009; Linkowski et al., 1994; Schmider et al., 1995) a decrease of
number of glucocorticoid receptors (Bei et al., 2009; Fries et al., 2014)
and a decreased sensitivity in the negative feedback response (Vieta
et al., 1999; Watson et al., 2004) in BD patients as compared to healthy
individuals. This has been found during episodes (state phenomenon)
and in between episodes (trait phenomenon). Results also indicate a
role in the staging of the disease, with a more severe dysregulation in
those with a higher number of mood episodes (Watson et al., 2004),
suggesting chronicity of both endocrine as mood dysregulation.
However, results concerning HPA-axis functioning in BD have been
conflicting and are difficult to interpret and compare across studies,
which may be due to 1) heterogeneity of patient groups, with differ-
ences in disease type, phase and stage, and, 2) methodological issues
regarding the assessment of the functioning of the HPA-axis by using
time point measures of cortisol in serum or saliva which are under the
influence of the circadian rhythm, diurnal pulsatile secretion, and acute
psychological or physiological stress. These constantly changing levels
complicate the interpretation of serum and saliva cortisol measure-
ments. By using analysis of cortisol in scalp hair, as a method to monitor
chronic HPA axis functioning, we can solve these shortcomings of time
point measures. This technique measuring hair cortisol concentrations
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(HCC) has been proven to be a useful marker of long-term systemic
cortisol. (Sauvé et al., 2007; van Uum et al., 2008; Manenschijn et al.,
2011)
Until now, only few studies have been published reporting HCC in
BD. Our group previously observed higher HCC in BD patients with an
older age of onset (Manenschijn et al., 2011). Streit et al. (2016) found
higher HCC in BD patients compared to controls (CON) and also found a
correlation between manic symptoms and HCC.
The aim of this study is to explore long-term cortisol in relationship
to relapses to a manic episode. We included an extensively defined
cohort of BD type I patients in a euthymic state, either with or without a
manic episode prior to hair sampling in order to distinguish between
state and trait. In addition, we explored the severity of the disease, by
studying the number of mood episodes and long-term cortisol exposure.
2. Materials and methods
2.1. Study design
This study is part of a large case-control study, the Dutch Bipolar
Cohort (DBC), investigating genetic and phenotypic information of
patients with bipolar disorder type I, first degree relatives and controls
(CON). The study design is described in more detail by Vreeker et al.
(2016), [PMID: 30303059]. In brief, patients were recruited via clin-
icians, the Dutch patients’ association for BD, pharmacies and adver-
tisements. Healthy controls were recruited via advertisements and
among individuals who previously participated in scientific studies and
agreed to be contacted for new research. Inclusion criteria were: 1) age
≥18 years, 2) at least three Dutch-born grandparents, 3) a good un-
derstanding of the Dutch language. Participants were considered to be
euthymic when they did not meet DSM-IV criteria for a mood episode,
according to the Structured Clinical Interview for DSM-IV (SCID-I).
Patients with somatic illness that could have influenced the diagnosis of
BD were excluded. This study was approved by the institutional review
board of UMCU. All participants provided written informed consent,
and all study procedures were executed in accordance with GCP
guidelines.
2.2. Participants
As shown in Fig. 1 we included all BD patients with a manic episode
in the 6 months prior to the baseline measurement, which were a total
of 41 BD patients. In addition, we selected 50 euthymic BD patients and
50 controls (CON), randomly using SPSS.
The patient group with a manic episode was divided in those with a
manic episode until 3 months prior the baseline measurement (N =
21); and those with a manic episode 4–6 months prior to the baseline
measurement (N = 20) (see Fig. 1). From these 20 patients, 9 were
excluded (6 hair samples were missing, and 3 samples were not suitable
for analysis due to low hair weight). In order to create equal groups we
selected 17 hair samples for each group, BD patients and CON, selected
by optimal hair length and thickness.
2.3. Patient characteristics and mental health
At baseline, all participants were interviewed by a trained inter-
viewer at the UMC Utrecht or one of their academic collaborative in-
stitutes to collect sociodemographic data, patient characteristics, so-
matic and psychiatric disease characteristics.
CON were interviewed using the Mini International
Neuropsychiatric Interview (Sheehan et al., 1998). CON with a psy-
chotic or bipolar disorder, or with first-degree relatives with psychosis
or BD, were excluded. BD patients were diagnosed using the Structured
Clinical Interview for DSM-IV Axis I disorders (SCID-I) by First et al.
(2002).
Age of onset was defined as age of first medication for the bipolar
disorder as reported in the Questionnaire of Bipolar Illness (QBP-NL ; an
adaptation of the Enrolment Questionnaire (Stanley Foundation Bipolar
Network). (Leverich et al., 2001; Suppes et al., 2001) The number of
episodes was defined using the QBP-NL as well.
All participants additionally filled out a questionnaire concerning
natural hair color, hair treatment (dyeing/bleaching/permanent), the
use of hair products on the day of sampling, the frequency of hair
washing (Stadler et al., 2013; Staufenbiel et al., 2015) and the use of
corticosteroids, as these are known to influence hair cortisol.
2.4. Hair sample collection
A scalp hair sample of approximately 100–150 hairs was obtained
from each participant at baseline. Samples were cut as close to the scalp
as possible at the posterior vertex. Each hair sample was taped on a
piece of paper with the proximal side marked, and stored on room
temperature till analysis (Fig. 2).
2.5. Hair sample preparation work-up and analysis
Each hair lock was divided into two segments: the proximal 0−3 cm
measured from the scalp, corresponding to the most recent 3 months
before collection, and the 3−6 cm measured from the scalp, corre-
sponding to the period 4–6 months before hair collection. Hair seg-
ments were further processed and analyzed separately as described
previously by Noppe et al. (2015).
In brief, from each hair segment approximately 12 mg was weighed.
Hair segments were washed in 2 mL of LC–MS grade isopropanol for 2
min, and left to dry. Extraction of steroids took place in 1.4 mL of
LC–MS grade methanol and 100 μL of internal standard, at 25 degrees
Celsius while the samples were gently shaken. After extraction, samples
were centrifuged at 4500 RPM for 5 min and 900 μL of the supernatant
was transferred to a clean glass tube. We then added 750 μL of LC–MS
grade methanol to the remaining supernatant and hair sample, and
after centrifugation we transferred an additional 900 μL of clear su-
pernatant, resulting in a 1.8 mL extract per hair segment. Extracts were
purified using solid phase extraction, and hair cortisol was quantified
on a Water Xevo TS-Q LC–MS/MS system (Waters, Milford MA).
2.6. Statistical analysis
Data were analyzed using SPSS 22.0 for Windows (IBM, Armonk,
NY). Differences between group characteristics were tested using Chi-
square and Mann Whitney U test because of non-normal distributions.
After logarithmic transformation, hair cortisol levels were normally
distributed. HCC are expressed as standardized means and 95 %
Confidence Interval. HCC between BD patients and CON were com-
pared using independent sample t-tests and ANCOVA, adjusted for the
following covariates; age, sex, BMI, hair washing frequency (Wester and
van Rossum, 2015). Linear regression analyses were conducted in the
BD group for the association between the number of different mood
episodes and HCC. A two-sided p value below 0.05 was considered
statistically significant.
3. Results
In total, 45 BD patients and 17 CON were enrolled in this study
(Fig. 1). No differences between groups were found regarding demo-
graphics, BMI, corticosteroid use and hair characteristics (Table 1).
3.1. Bipolar patients versus healthy controls
Slightly higher HCC were found in BD patients compared to CON
(Fig. 3). In the period 1 through 3 months prior sampling, HCC stan-
dardized mean in BD was: 5.12 pg/mg hair (95 % CI: 3.92–6.70)
(standardized β 0.265; p = 0.048). After adjustment for sex, age, BMI
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and hair washing frequency the standardized β was 0.164; p = 0.185.
In CON the standardized mean was 3.12 pg/mg hair (95 % Confidence
Interval (CI):1.96–4.93) (Fig. 3). In the period 4 through 6 months prior
to sampling, HCC standardized mean in BD was: 3.97 pg/mg (95 % CI:
2.83–5.57)(standardized β 0.293; p = 0.031). After adjustment for sex,
age, BMI and hair washing frequency β is 0.197; p = 0.118. In CON the
standardized mean was 2.03 pg/mg hair (95 % CI: 1.29–3.20).
Furthermore, we found higher HCC in the hair samples representing
4 through 6 months prior to sampling in those BD patients with a manic
episode 1 through 3 months prior to sampling as compared to the hair
samples representing 1 through 3 months. This is indicating a preceding
peak in the cortisol level followed by a manic episode (β = 0.834; p =
0.041 after correction β = 0.732; p = 0.118) (Fig. 3). No differences
were found between the different disease states.
3.1.1. Number of episodes
A positive association was found between the number of mood
episodes before study entry and HCC (standardized β = 0.462, p =
0.005 (0 till 3 months prior sampling) and standardized β = 0.382, p =
0.032 (4 till 6 months prior sampling)). This association was shown for
both manic as well as depressive episodes (Table 2).
4. Discussion
In this pilot study we found a relationship between increased Hair
Cortisol Concentrations (HCC), indicative of increased HPA activity,
and a higher probability of a manic episode in BD patients type I.
Second, we show a positive association between HCC and the number of
previous episodes, representing the disease chronicity.
In the current study we aimed to unravel whether increased cortisol
exposure is a condition preceding a mood episode or rather a con-
sequence of a manic or depressive episode. Our data indicate a potential
temporal relationship between long-term cortisol and direct risk of
(manic) relapse in disease. We observed higher HCC in the patient
group with a recent manic episode (1 through 3 months prior to sam-
pling) based on a higher HCC in the hair sample representing the period
4 through 6 months, which suggest a peak in cortisol occurs prior to a
manic episode. However, after correction for the most common
Fig. 1. Flow chart study population.
*Hair weight too low.
Fig. 2. Hair sample analyses.
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covariates (age, sex, BMI, hair washing frequency) (Wester and van
Rossum, 2015) the higher HCC did not reach significance. Correction
for medication didn’t influence the outcome and lowers the power of
analyses. The higher HCC is in line with the study of Vieta et al. (1999)
who compared 42 lithium treated remitted bipolar I patients to 21
healthy controls in adrenocorticotropic hormone (ACTH) response after
a corticotropin-releasing hormone (CRH) stimulation and found an
enhanced response in the BD group (higher baseline ACTH). When
comparing the patients who relapsed to patients who did not, a sig-
nificantly higher ACTH response to CRH was seen in the period before
(hypo)manic symptoms became clinically apparent.
With respect to disease severity (or chronicity), we found a re-
lationship between higher HCC and the severity of BD, quantified by
the number of depressive and manic episodes. This is in line with
findings by Fries et al. (2014), regarding a higher (post-dexamethasone)
cortisol level in the late stage BD patients; in those with a higher
number of episodes and a reduced glucocorticoid receptor activity.
Until now, only a few published studies measured long-term cortisol
using hair analysis (HCC) in BD patients16 17. In our own previous work,
Manenschijn et al. (2011), we compared 195 healthy controls and 100
BD patients with different subtypes and different disease states. The
study showed significantly higher cortisol levels in BD patients with an
age of onset older than 30 years, but no relationship in the earlier onset
BD patients. In addition, an association with manic episodes could not
be evaluated due to a lack of patients with a recent manic episode. In
contrast to our study, Manenschijn et al. included both BD type I and II
patients with as well recent depressed and hypomanic episodes. In the
present cohort only BD type I patients with a reliably diagnosed manic
episode were included, increasing homogeneity which helps to under-
stand the underlying switch process.
Another study by Streit et al. (2016) compared 61 BD type I patients
(38 inpatients, 23 outpatients) with 159 schizophrenia patients and 82
healthy controls. They found increased HCC in BD patients compared to
healthy controls and higher HCC in BD inpatients than outpatients
which indicated a relationship with mood episodes.
Also contra dictionary results were found, as Maripuu et al. (2017)
found a negative association between HPA-axis activity and age in bi-
polar patients, especially those with a longer disease duration and
without prophylactic medication. Maripuu et al. compared 159 bipolar
Table 1
Demographic characteristics of sample.
Total group Total group P - value
Controls Bipolar patients
(N = 17) (N = 45)
Sociodemographics
Male; n (%) 3 (17.6) 14 (31.1) 0.289
Age (year); median (IQR) 41 (25.5–48.0) 46 (36.0−53.0) 0.136
Health Factors





Use of Corticosteroidsa (%) 1(5.9) 0 (0) 0.104
Hair characteristics
Hair color (%)
Black 0 (0) 4 (8.9) 0.210
Brown 5 (29.4) 19 (42.2) 0.364
Blond 9 (52.9) 16 (35.6) 0.220
Grey 3 (17.6) 5 (11.1) 0.501
Hair treatment (%) 5 (29.4) 22 (48.9) 0.168
Use of Hair products (%)b 9 (52.9) 19 (42.2) 0.651
Hair washing; times a week (%)
1−2 times 3 (17.6) 14 (31.1) 0.297
3−4 times 8 (47.1) 15 (33.3) 0.326
> 4 times 6 (35.3) 15 (33.3) 0.887
Disease characteristics




Number of episodes: total;
median (IQR)
6.0 (5.0−11.0)
: manic episodes; median (IQR) 4.0 (3.0−5.0)
Abbreviations: P, P-value<0.05; IQR, Interquartile Range.
a Fluticasonpropionaat (nasal spray).
b Hairproducts: hairspray, wax, mouse, gel and other.
Fig. 3. Results hair cortisol concentration
without correction.
HCC in logarithmic scale; Geometric
mean± SEM; * p< 0.05.
CON; BD Bipolar Disorder; BD: M 1-3 Bipolar
Disorder with a manic episode in the period 1
through 3 months prior sampling (N = 17);
BD: M 4-6 Bipolar Disorder with a manic epi-
sode in the period 4 till 6 months prior sam-
pling (N = 11); BD: Euth: Bipolar Disorder
euthymic state.
Table 2
Overview of predictors for Hair Cortisol Concentration (HCC).
HCC in 0 till 3
months prior
sampling
HCC in 4 till 6 months
prior sampling
β P-value β P-value
Bipolar disorder (yes or no) 0.265 0.049 0.293 0.030
* 0.164 0.222 0.197 0.139
Number of mood episodes total 0.532 0.002 0.496 0.010
* 0.462 0.005 0.382 0.032
manic 0.421 0.012 0.397 0.020
* 0.364 0.013 0.347 0.022
depressive 0.533 0.002 0.419 0.024
* 0.413 0.011 0.276 0.118
Abbreviations: HCC, Hair Cortisol Concentration in picogram per miligram (pg/
mg); Number of mood episodes, number of mood episodes in life time definite
by Structured Clinical Interview for DSM-IV axis I diagnoses (SCID-I); β, beta
was calculated with logistic regression; P-value<0.05.
*Adjusted: for age, sex, BMI and hair washing frequency.
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out patients and 258 controls.
The observed peak in cortisol prior to a manic episode is a unique
finding indicating (hyper-) activation of the HPA-axis preceding a
manic episode. The question then arises whether this elevation is
causing the subsequent mood episode, or maybe both the increasing
cortisol as well as the mood episode are triggered by for example en-
vironmental stress. Based on findings in somatic diseases like Cushing’s
disease, in which the severe hypercortisolism preceeds the mood dis-
orders, it is biologically plausible that also in bipolar disorder a biolo-
gical dysregulation of the HPA-axis induces the mood episode.
Moreover, the relationship between late stage bipolar disorder (as re-
flected by a higher number of episodes) and higher longterm cortisol
levels and number of episodes underlines the interconnectedness of the
endocrine process of cortisol regulation and mood stability, with the
risk of chronicity of dysregulation of both cortisol and mood dysregu-
lation. This study has several strengths. First, we investigated the re-
lationship between HCC and BD and its mood episodes using a reliable
long-term measure of cortisol. HCC provide insight into the chronic
potential dysregulation of the HPA axis rather than acute measurements
as has been used in earlier research. Hair cortisol analysis seems more
suitable to provide this long-term estimate, as they are not influenced
by the circadian rhythm, the pulsatile secretion of cortisol and the
fluctuation by stress reactions as cortisol in saliva or serum. HCC pave
the way to a “timeline approach”, showing the interrelationships be-
tween cortisol and mood episodes over time. Second, we included a
relatively homogeneous and very well defined group of BD type I pa-
tients and therefore avoided the potential pathophysiological differ-
ences between the subtypes of BD, as we previously found in our studies
in BD patients16. Third, we used a LC–MS/MS based method, which the
current golden standard for measuring steroid hormones in scalp hair
such as HCC (Russell et al., 2015).
The first and most important limitation of this study is the small
sample size which is directly related to the main question of the study,
understanding the role of the HPA-axis in extensively defined and well
described cohort of BD type I patients with a manic or euthymic episode
in the last six months prior to inclusion. This requires the recruitment of
a large cohort of BD patients, as we did, yielding the relatively low, but
well phenotyped, numbers of specifically BD type I patients. The second
argument to agree with this sample size was the purpose of the study, as
it was set up as a pilot study. In this line we accepted the lack of sig-
nificance in the adjusted analyses.
The second limitation is the lack of repeated measurements for the
mood severity. This information will have given us better insight in the
changes of mood, as well as the determination of the euthymic state.
Third and last limitation are the (lack of) exclusion criteria for co-
morbidities and is connected to the first and most important limitation.
After excluding the comorbidities from analyses the basic outcome stays
the same although with loss of power of the statistical analyses.
To conclude, in the present study we found preliminary evidence for
a relation between higher HCC and the risk of a manic relapse as well as
a higher number of previous mood episodes in the course of BD type I.
However, larger samples are needed to confirm our findings. This might
prelude on future studies to cortisol levels in relation to mood episodes
in BD including timelines. Because of the potential serious side effects
of the manic episode during the course of BD, our finding is promising
in providing new options in optimizing treatment of BD by early re-
cognition of vulnerable periods.
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